CLGN

CollPlant Biotechnologies Ltd.
CAPPED RATING

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CollPlant Biotechnologies Ltd. (CLGN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Growth (D-). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.8 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -10.0
EV / EBITDA -0.5
Rev Growth YoY -39.7%
Gross Margin 0.0%
Price Return 3M 22.4%
Price Return 12M -80.4%
Catalyst Signal 0.00
Market Cap $12.0M
TTM Revenue $318.0K
Price / Sales 37.8
ROE -162.0%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.8) D- (0.9) C- (2.1) C+ (2.8) C+ (2.6) C (2.2)
2026-11-04 C+ (2.8) D- (0.8) C- (2.1) C+ (2.6) C+ (2.7) C (2.2)
2026-10-28 C+ (2.8) D- (0.8) C- (2.0) C+ (2.7) C+ (2.7) C (2.2)
2026-10-21 B- (2.9) D- (0.8) C- (2.0) C+ (2.8) C+ (2.6) C (2.2)
2026-10-14 B- (2.9) D- (0.8) C- (2.0) B- (2.9) C+ (2.6) C (2.2)
Page 1 of 4